We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Selvita Sa | LSE:0RKT | London | Ordinary Share | PLSELVT00013 | SELVITA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 57.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 67.99M | -92.11M | -3.9841 | -14.31 | 1.32B |
From Jun 2019 to Jun 2024
KRAKOW, Poland, Nove. 6, 2019 Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that two abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL, taking place from December 7-10, 2019.
Details of the poster presentations are as follows:
Poster Presentation: SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial
Abstract Number: 2651
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date: Sunday, December 8, 2019
Time: 6:00 p.m. – 8:00 p.m. PST
Location: Orange County Convention Center, Hall B
Poster Presentation: CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation
Abstract Number: 3774
Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III
Date: Monday, December 9, 2019
Time: 6:00 p.m. – 8:00 p.m. PST
Location: Orange County Convention Center, Hall B
To view these abstracts, please visit the American Society of Hematology website located at http://www.hematology.org/Annual-Meeting/Abstracts.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology. Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets. SEL120 is a selective CDK8 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia.
For more information, please see www.ryvu.com.
View original content:http://www.prnewswire.com/news-releases/ryvu-therapeutics-announces-presentations-on-cdk8-inhibitor-sel120-at-the-61st-ash-annual-meeting-300953013.html
SOURCE Ryvu Therapeutics S.A.
Copyright 2019 PR Newswire
1 Year Selvita Chart |
1 Month Selvita Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
